Charles Russell Speechlys advises Kreos Capital on its €15 million growth capital investment
Charles Russell Speechlys LLP advised Kreos Capital V (UK) Limited on its €15 million growth capital investment in Kiadis Pharma NV (“Kiadis Pharma”), a Dutch company listed on Euronext Amsterdam and Euronext Brussels.
Kiadis Pharma is a clinical stage biopharmaceutical company developing innovative products to make bone marrow transplantations safer and more effective for patients suffering from blood cancers and inherited blood disorders. Its product candidates have the potential to make allogeneic hematopoietic stem cell transplantations (HSCT) safer and more effective for patients.
Kiadis Pharma announced to the market that it will use the financing to advance the development of its ATIR products, for general corporate purposes and to repay €5.3 million of existing Dutch Government Loans.
The Charles Russell Speechlys core team comprised Chris Putt (Partner), Rossana Conti (Senior Associate) and Amelly Kok (Associate) from our Corporate Team. Fruytier Lawyers in Business advised on matters of Dutch law and Borden Ladner Gervais LLP on matters of Canadian law respectively.
News & Insights
Charles Russell Speechlys advises ALDO UK's administrators, RSM, on the sale of the business and assets
Our Corporate Restructuring & Insolvency team has advised ALDO UK's administrators, RSM, on the sale of the business and assets.
Charles Russell Speechlys sponsor The Sunday Times Fast Track 100 ‘Outstanding Achievement’ award
Taking a glimpse into the 23rd Sunday Times Fast Track virtual conference and awards dinner.
Pharmacy Brief - September 2020
The September edition of our Pharmacy Brief
Relief for Private Dental Practices? – Update following the verdict of the FCA’s business interruption insurance test case
Providing clarity on compensations for dental practices who were forced to close due to the COVID-19 pandemic.